BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational HighlightsGlobeNewsWire • 05/08/23
The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEOInvestors Business Daily • 05/04/23
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care ConferenceGlobeNewsWire • 05/02/23
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023GlobeNewsWire • 04/24/23
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public OfferingGlobeNewsWire • 03/14/23
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational HighlightsGlobeNewsWire • 03/09/23
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023GlobeNewsWire • 02/23/23
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers SymposiumGlobeNewsWire • 02/13/23
BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company's Investigational, Oral Innate Immune Activator for Rare Form of Prostate CancerGlobeNewsWire • 02/08/23
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate CancerGlobeNewsWire • 01/11/23
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/22/22
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer's DiseaseGlobeNewsWire • 12/19/22
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap ConferenceGlobeNewsWire • 12/01/22
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or SchizophreniaGlobeNewsWire • 11/30/22